Evidence map›Paper›PMID 26546306›Full record

Observational studyHeart and vessels2016

Use of antiarrhythmic drugs during ablation of persistent atrial fibrillation: observations from a large single-centre cohort.

Jakob Lüker, Arian Sultan, Susanne Sehner, Boris Hoffmann, Helge Servatius, Stephan Willems, Daniel Steven

Open access · bronzeAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jakob LükerDepartment of Electrophysiology, University Hospital Cologne, Kerpener Strasse 62, 50937, Cologne, Germany. jakob.lueker@me.com.
Arian SultanDepartment of Electrophysiology, University Hospital Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
Susanne SehnerUniversity Hospital Eppendorf, Martinistrasse 52, 20249, Hamburg, Germany.
Boris HoffmannUniversity Hospital Eppendorf, Martinistrasse 52, 20249, Hamburg, Germany.
Helge ServatiusUniversity Hospital Bern, 3010, Bern, Switzerland.
Stephan WillemsUniversity Hospital Eppendorf, Martinistrasse 52, 20249, Hamburg, Germany.
Daniel StevenDepartment of Electrophysiology, University Hospital Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
University Hospital Cologne · DEUniversität Hamburg · DEUniversity Hospital of Bern · CHUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Catheter ablation of complex fractionated atrial electrograms (CFAE), also known as defragmentation ablation, may be considered for the treatment of persistent atrial fibrillation (AF) beyond pulmonary vein isolation (PVI). Concomitant antiarrhythmic drug (AAD) therapy is common, but the relevance of AAD administration and its optimal timing during ablation remain unclear. Therefore, we investigated the use and timing of AADs during defragmentation ablation and their possible implications for AF termination and ablation success in a large cohort of patients. Retrospectively, we included 200 consecutive patients (age: 61 ± 12 years, LA diameter: 47 ± 8 mm) with persistent AF (episode duration 47 ± 72 weeks) who underwent de novo ablation including CFAE ablation. In all patients, PVI was performed prior to CFAE ablation. The use and timing of AADs were registered. The follow-ups consisted of Holter ECGs and clinical visits. Termination of AF was achieved in 132 patients (66 %). Intraprocedural AADs were administered in 168/200 patients (84 %) 45 ± 27 min after completion of PVI. Amiodarone was used in the majority of the patients (160/168). The timing of AAD administration was predicted by the atrial fibrillation cycle length (AFCL). At follow-up, 88 patients (46 %) were free from atrial arrhythmia. Multivariate logistic regression analysis revealed that administration of AAD early after PVI, LA size, duration of AF history, sex and AFCL were predictors of AF termination. The administration of AAD and its timing were not predictive of outcome, and age was the sole independent predictor of AF recurrence. The administration of AAD during ablation was common in this large cohort of persistent AF patients. The choice to administer AAD therapy and the timing of the administration during ablation were influenced by AFCL, and these factors did not significantly influence the moderate single procedure success rate in this retrospective analysis.

Indexed as

Catheter AblationAgedAmiodaroneAnti-Arrhythmia AgentsAtrial FibrillationElectrocardiographyElectrophysiologic Techniques, CardiacFemaleHeart Conduction SystemHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisPulmonary VeinsRetrospective StudiesAmiodaroneAnti-Arrhythmia AgentsAntiarrhythmic drugsCatheter ablationDefragmentationIntraprocedural administrationPersistent atrial fibrillation

Identifiers

PMID26546306
OpenAlexW2144754692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.